BIO half-month big pump 270%, DeSci track collectively "revived"

Author: Nicky, Foresight News

The token BIO of Bio Protocol has recently performed remarkably. According to Bitget data, the price of BIO started at $0.056 on August 6, 2025, and climbed to a peak of $0.2081 on August 22, with an increase of over 270% during this period.

Currently, the staking scale of BIO has reached approximately 174 million coins, accounting for about 9.3% of the total circulating supply of 1.854 billion coins. At the same time, BIO has been listed on several major exchanges, including Binance, Coinbase, Bithumb, etc.

By the end of 2024, the DeSci craze lasted only a few months. After BIO was listed on Binance, its token performance can be described as "disastrous". After reaching a historical high of 0.8 USD shortly after its launch, it continued to decline, and by August 2025, the token price was hovering around 0.05 USD, more than 90% down from its historical peak. So what exactly revived BIO?

Tracing back to the project's origin, on November 8, 2024, Binance Labs (now YZi Labs) announced an investment in Bio Protocol. Although the investment details were not disclosed, this move signifies mainstream capital's recognition of the DeSci track.

As a representative project in the DeSci field, the core goal of Bio Protocol is to "transform the funding and commercialization model of early biotechnology research" and to build a network of biotechnology DAOs.

By leveraging blockchain technology, scientists, patients, and investors around the world can collaboratively participate in new drug development, addressing the pain points of traditional research where "funding is concentrated in large pharmaceutical companies and results are closed off." This helps global participants to fund and jointly engage in new drug development, particularly for issues related to rare diseases, longevity research, and emerging health challenges.

On June 3, 2025, the DeSci project token PYTHIA began to rise, increasing from $0.0168 to $0.122 on August 14, a growth of 626%.

On July 31, 2025, Coinbase launched both BIO and RSC tokens for DeSci projects, marking the return of DeSci to the view of the mainstream cryptocurrency market in the West.

Since then, the token VITA of the DeSci project VitaDAO has risen from $1.17 on August 1 to a high of $2.22 on August 22, a total increase of 89%. The token NEURON of Cerebrum DAO also performed well in August, with an increase of over 180% this month. Meanwhile, the CryoDAO token CRYO saw an increase of over 200% this month, the ValleyDAO token GROW increased by 76% this month, and the HairDAO token HAIR increased by 67.5% this month. It can be seen that DeSci is on the rise.

Aubrai: How AI Scientists are Redefining the Rules of Longevity Research?

Entering 2025, Bio Protocol accelerates iteration. On August 21, Bio Protocol, in collaboration with VitaDAO, launched the first BioAgent Launch project Aubrai, marking the official implementation of its "decentralized research agency" plan. This sale lasted only 24 hours, with users participating by staking BioXP and investing in BIO tokens. The TGE of the token AUBRAI will take place on August 25.

The tokenomics of AUBRAI has been published, with a total supply of 2 million tokens. The token distribution is as follows: 20% for sale, 6% for liquidity pools, 15% allocated to the treasury, 20.1% distributed to initial backers, 10% for the LEV Foundation, 22% for VitaDAO, and 6.9% for Bio Protocol.

Aubrai is based on data from the private laboratory of longevity research pioneer Dr. Aubrey de Grey, who proposed the "Strategies for Engineered Negligible Senescence" (SENS), aimed at preventing age-related diseases by repairing the damage to aging cells in the human body. He holds a Bachelor's degree in Computer Science and a PhD in Biology from Cambridge University and has authored works such as "The Mitochondrial Free Radical Theory of Aging" (1999) and "Ending Aging" (2007).

de Grey is currently the Chairman and Chief Science Officer of the LEV Foundation. The foundation focuses on longevity research, with its flagship project "Robust Mouse Rejuvenation" testing late-stage intervention therapy combinations through large-scale mouse lifespan experiments. These experiments are conducted in collaboration with Ichor Life Sciences, emphasizing damage repair methods while avoiding early interventions such as gene modification to accelerate clinical translation to humans.

Another LEV project "Transplants on Demand" explores tissue engineering, funding Keinice Bio's cryopreservation technology, which uses ultra-cold helium to achieve organ vitrification preservation. This avoids the toxicity issues of traditional cryoprotectants, aiming to provide "off-the-shelf" young organ replacements to address organ failure caused by aging.

The LEV Foundation also supports the Alliance for Longevity Initiatives, a 501(c)(4) nonprofit organization aimed at promoting policy support from the U.S. government for longevity research. By collaborating with relevant experts, it seeks to raise public awareness of aging-related chronic diseases and advocate for national funding.

Through these studies, its private laboratory has accumulated thousands of unpublished research notes, internal experimental data, and collective knowledge in the field of global longevity. These "private research assets," which were previously restricted to the core team, are now integrated by Aubrai as training data.

In practice, Aubrai has transformed the workflow of the de Grey team. It manages over a dozen complex longevity studies, compressing what would normally take weeks of manual review into just a few days. It also identifies dosage conflicts, timing mismatches, and hidden biases, even uncovering new issues that the team was previously unaware of.

According to the official roadmap, Aubrai has currently received joint funding from Bio Protocol and VitaDAO for the RMR2 pilot study, aimed at validating candidate interventions and optimizing the delivery method; community scientists can experience their collaborative capabilities as "co-scientists" through the closed beta version of the CHAT UI. At the same time, the wallet supports a self-hosted EOA wallet built on the Coinbase Developer Platform, with limited transaction authorization capabilities.

In the future plan, Aubrai will launch a semi-autonomous agent (integrating Base AgentKit, supporting full trading execution and financial autonomy) in the fourth quarter of 2025, and will open the FAILURE DB database (recording negative outcomes and design flaws to avoid repeated mistakes), ultimately achieving "fully autonomous research" — a complete scientific output process from hypothesis generation, experimental design to wet experiment execution and paper publication.

V2 Upgrade: Build an Efficient Cycle of "Research - Capital"

The landing of Aubrai is inseparable from the support of the Bio Protocol V2 version. Its V2 version adopts the "launch and grow" concept, achieving sustainable growth through a community-driven launchpad:

• Low Valuation Launch: Referring to platforms like Pump.fun, the initial valuation of the project is reduced to $205,000 FDV, with 37.5% of the tokens sold directly, and each user can subscribe to a maximum of 0.5% of the total tokens sold;
• Sustainable Liquidity: All funds raised after the initial offering (BIO tokens) will automatically generate an LP pool, combined with 12.5% of the supply tokens. A 1% transaction fee will be charged on each trade in the secondary market (70% goes to the project treasury, 30% to the protocol), forming a positive cycle of "active trading - increase in research funds - advancement of results - resurgence of market enthusiasm."
• Points Incentive Mechanism: Users can earn BioXP points through actions such as staking, governance voting, community promotion, and participating in new launch projects. Points can be used to participate in allocation subscriptions for undervalued projects.

The implementation of these mechanisms has upgraded Bio Protocol from a "scientific research financing platform" to a "scientific research ecological operating system," which not only addresses funding issues but also enhances the conversion efficiency of research results through community incentives and automated tools.* (Related reading: "Will the Bio version upgrade open the flywheel system and create the ultimate platform for DeSci capital efficiency?")

DeSci's "Long-termism" and the Future

The market performance of BIO and the landing of Aubrai have brought the DeSci track back into the public eye. However, the challenges in this field have never disappeared: the research cycle is long (even with Aubrai accelerating experiments, it still takes years for longevity therapies to go from the lab to clinical trials), market patience is short (crypto investors are used to "fast rises and fast falls"), and regulatory uncertainty (the compliance costs involved in human trials are high).

In this regard, Binance founder Zhao Changpeng stated in an exclusive interview with Foresight News: "DeSci and Meme coins are completely two extremes. DeSci projects have a long cycle, while investors' attention in the digital currency industry is generally short. Meme coins are very popular, and such projects are not given much attention. However, in the long run, these projects have a significant contribution to humanity and society. I believe they will definitely develop in the future, just not sure about the specific time."